Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial Academic Article uri icon

Overview

MeSH Major

  • Carcinoma
  • Heart Neoplasms
  • Melanoma
  • Neoplasms
  • Sarcoma

abstract

  • Onconova Therapeutics, Leukemia & Lymphoma Society.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(16)00009-7

Additional Document Info